On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Continues Advancement of Clinical Program

  • Multiple important steps have contributed to the advancement of the BriaCell clinical program in 2018
  • The company has gotten excellent results from its Bria-IMT clinical trials and hopes to begin Bria-OTS testing in 2019
  • The personalized, off-the-shelf advanced breast cancer treatment will be much more cost-effective to manufacture than alternatives and is expected to produce fewer side effects

Throughout 2018, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) has been working hard on the advancement of its clinical program. The company attained crucial safety and efficacy data via its clinical trials, and it also achieved proof of concept. The phase I/IIa study of its proof of concept clinical trial in advanced breast cancer achieved sustained tumor shrinkage at various sites in several patients. These results confirm the data collected through two previous trials, demonstrating the promising effect of the company’s Bria-IMT therapy in the treatment of advanced, metastatic breast cancer.

At the beginning of November 2018, BriaCell CEO Dr. William Williams said in an interview with Stock Day’s Everett Jolly that the company is developing the first personalized, off-the-shelf immunotherapy for advanced breast cancer (http://ibn.fm/9SMfU). The key developments are focused in two fields and programs – Bria-IMT and Bria-OTS.

Bria-IMT has undergone extensive clinical testing, demonstrating tumor shrinkage in patients with advanced breast cancer. Currently, Bria-IMT is in Phase IIa clinical testing in combination with KEYTRUDA® (pembrolizumab), manufactured by Merck & Co., Inc. (NYSE: MRK). Bria-IMT stimulates T-cell activity – one of the body’s natural defense mechanisms. In combination with KEYTRUDA, Bria-IMT is expected to accomplish an amplification effect to strengthen the anti-tumor activity of the treatment.

Bria-OTS is still in the process of development. Work is based on the results obtained in the Bria-IMT clinical trials. BriaCell Therapeutics plans to genetically engineer immunotherapy cell lines that can induce a specific response against cancer. The cell lines are pre-manufactured, but the personalized treatment can be selected and administered to the patient based on his or her specific HLA alleles. In this way, the immune response is tailored to the individual patient, so the treatment should not have a negative impact on the overall functioning of the immune system, Dr. Williams said.

The creation of tailored off-the-shelf immunotherapy solutions will eventually cover 90 percent of the population. Bria-OTS does not necessitate a personalized manufacturing process, which keeps the cost and the production time down, Dr. Williams added. Bria-OTS is anticipated to initiate clinical trials in 2019.

By 2021, immunotherapy solutions that target cancer are expected to turn into a $100 billion industry. Through previous research, clinicians have been capable of delivering personalized treatments for cancer that can address the specific condition of an individual patient. These treatments, however, have been costly to produce (due to individual manufacturing), and they’ve been associated with specific side effects. The BriaCell approach should be less costly and have fewer side effects than currently approved personalized immunotherapies.

Breast cancer is the most commonly occurring form of malignancy in women and the second most common overall cancer. In the U.S. alone, 12.3 percent of women will receive a diagnosis of breast cancer in their lifetime (http://ibn.fm/QaUGj).

The development of innovative therapies has increased the survival rate of breast cancer patients. The five-year survival rate has gone up from 74.8 percent in 1975 to 90.7 percent in 2011 for patients diagnosed with breast cancer. Despite this, over 40,000 women will die of breast cancer in the United States in 2018, indicating a very large unmet need.

BriaCell Therapeutics is based in Berkeley, and its headquarters are located in Vancouver, British Columbia. The company specializes in clinical-stage biotechnology and targeted immunotherapy for advanced breast cancer.

For more information, visit the company’s website at www.BriaCell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered